Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964813 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL626017 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL27379896 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL476260 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL476259 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL18018299 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL21441862 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3TSHRPREP | |
| SCHEMBL19654088 | 0.90 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL17040995 | 0.90 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPPTPN1 | |
| SCHEMBL22086379 | 0.90 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | ORION CORPORATION (FI) | 2006-10-12 | — | — | US | disclosed |
| EP-1581489-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004060862-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | PREP, DNPEP, IDE | CHRM2 1698/4885CHRM1 1707/4885CHRM3 3072/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | CHRM2 2473/4885CHRM1 2859/4885CHRM3 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.